Weekly Report
·
Strategic Signals Weekly
Licensing deals, strategic reviews, and financing events from SEC 8-K filings.
18
Total Signals
1
Licensing Deals
2
Strategic Reviews
14
Financing Events
Weekly Signal Volume
Licensing
Strategic
Financing
This week
Strategic Reviews
Companies exploring strategic alternatives, potential M&A, or board-level reviews.
| Company | Date | Details |
|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | Feb 24, 2026 | ...release announcing that it plans to explore strategic alternatives and has engaged Piper Sandler & Co. as its exclusive financial advisor to assist in the strategic evaluation. A copy of the press release is furnished as Exhibit 99.... [SEC] |
| Genprex, Inc. (GNPX) | Feb 23, 2026 | ...prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including... [SEC] |
Licensing & Partnerships
New collaboration agreements, licensing deals, and partnership announcements.
| Company | Date | Details |
|---|---|---|
| Vir Biotechnology, Inc. (VIR) | Feb 23, 2026 | ...Astellas) entered into a Collaboration and License Agreement (the Agreement). Upon closing of the transaction contemplated by the Agreement (the Closing and the Transaction, respectively), Vir Bio and Astellas will enter into a global strategic collaboration... [SEC] |
Financing Events
Capital raises, ATM programs, debt offerings, and other financing activities.
| Company | Amount |
|---|---|
| Larimar Therapeutics, Inc. (LRMR) | $107.6M public offering [SEC] |
| Xenon Pharmaceuticals Inc. (XENE) | atm [SEC] |
| TANDEM DIABETES CARE INC (TNDM) | $290.7M private placement [SEC] |
| Kymera Therapeutics, Inc. (KYMR) | atm [SEC] |
| Zura Bio Ltd (ZURA) | $134.6M public offering [SEC] |
| AbbVie Inc. (ABBV) | $7,950.0M debt offering [SEC] |
| Palvella Therapeutics, Inc. (PVLA) | $187.3M public offering [SEC] |
| Vir Biotechnology, Inc. (VIR) | $141.1M public offering [SEC] |
| Bicara Therapeutics (BCAX) | $161.8M public offering [SEC] |
| ABBOTT LABORATORIES (ABT) | debt offering [SEC] |
| 4 more. View them all on the RxDataLab platform → | |
About This Data
Strategic signals are extracted from SEC 8-K filings using keyword analysis. We identify three categories:
- Strategic Reviews: Companies exploring "strategic alternatives," potential sales, or board-level reviews
- Licensing Deals: Collaboration agreements, licensing arrangements, and partnership announcements
- Financing Events: Capital raises, ATM offerings, debt issuances, and other financing activities
Data from RxDataLab and the SEC.